TrialsgrambetaRCTs are beautiful
AHA Scientific Sessions 2026Presentado sáb, 7 nov · 15:45 GMT-6LBS.03 Late-breaking Science: Hot Topics in CVD PreventionTodos los ensayos Late-Breaking Science →

Ez-PAVE

2026

Ez-PAVE: Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease, prespecified second randomisation

In patients with atherosclerotic cardiovascular disease, initial statin-ezetimibe combination therapy did not reduce the 3-year composite of cardiovascular death, myocardial infarction, stroke, revascularisation or hospitalisation for unstable angina compared with statin monotherapy.

Resultado

Eficacia: Cardiovascular outcomes within 3 yearshazard ratio 1,07 (IC del 95% 0,83-1,37) · P = 0,596

Por debajo de 1 a favor de initial statin-ezetimibe combination therapy, por encima de 1 a favor de statin monotherapy.

Tasas de eventos
Diferencia absoluta
0,6 puntos

La diferencia absoluta se deriva de las tasas de eventos.

También se informa: Median LDL-C during follow-up was 53 mg/dL (interquartile range 45-62) vs 62 mg/dL (interquartile range 53-74) with intensive targeting, and 63 mg/dL (interquartile range 55-73) vs 70 mg/dL (interquartile range 62-81) with conventional targeting. The safety end points were similar between the groups.

Publicación original
Subtema
Ezetimibe combination
Diseño
Open-label 2-by-2 factorial randomised trial in Korea (Yonsei University). First randomisation: LDL-C target below 55 versus below 70 mg/dL. The prespecified second randomisation, presented here: statin-ezetimibe combination versus statin monotherapy
Incluidos
3048 pacientes
Fuente
Lee SH, Byun YS, et al. Circulation. 2026; published online 7 November.doi 10.1161/CIRCULATIONAHA.126.083811

Discusión y crítica

Starting with statin-ezetimibe combination therapy lowered LDL-C during follow-up under both targeting strategies but did not reduce the primary composite endpoint compared with statin monotherapy. The composite includes any revascularisation and hospitalisation for unstable angina, so softer components may weigh on the total, and the abstract does not break the endpoint down into its components. Follow-up is three years, which may be too short to show a difference in hard outcomes from a modest gap in LDL-C. The abstract reports safety only as similar between groups and gives no figures.

Comentado en pódcasts